Acalabrutinib Metabolite 27 manufacturers
- ACP-5862
-
- $1520.00 / 25mg
-
2024-10-28
- CAS:2230757-47-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Acalabrutinib Metabolite 27 Basic information |
| Product Name: | Acalabrutinib Metabolite 27 | | Synonyms: | Acalabrutinib Metabolite 27;Acalabrutinib?active?metabolite?M27;4-[8-amino-3-[1-oxo-4-[(1-oxo-2-butyn-1-yl)amino]butyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-Benzamide;ACP-5862;Benzamide, 4-[8-amino-3-[1-oxo-4-[(1-oxo-2-butyn-1-yl)amino]butyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-;Acalabrutinib Impurity 1;Acalabrutinib Metabolite 27 (ACP-5862);Acalabrutinib Metabolite (M27) ACP-5862 D4Q: What is
Acalabrutinib Metabolite (M27) ACP-5862 D4 Q: What is the CAS Number of
Acalabrutinib Metabolite (M27) ACP-5862 D4 | | CAS: | 2230757-47-6 | | MF: | C26H23N7O3 | | MW: | 481.51 | | EINECS: | | | Product Categories: | | | Mol File: | 2230757-47-6.mol |  |
| | Acalabrutinib Metabolite 27 Chemical Properties |
| density | 1.34±0.1 g/cm3(Predicted) | | pka | 11.35±0.70(Predicted) | | form | Solid | | color | White to off-white |
| | Acalabrutinib Metabolite 27 Usage And Synthesis |
| Uses | 4-[8-Amino-3-[1-oxo-4-[(1-oxo-2-butyn-1-yl)amino]butyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-benzamide is a metabolite of Acalabrutinib (A115605) which is an experimental anti-cancer drug and a selective Bruton''s tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL). | | in vivo | Following a single oral dose of 100 mg Acalabrutinib, the half‐life of ACP‐5862 is 6.9 hours and the mean exposure is approximately twofold to threefold higher than that of Acalabrutinib[2].
ACP-5862 (M27) is the major single metabolite in the systemic circulation and accountes for 57.4% and 42.1% of the AUC0-t total radioactivity in male and female rat plasma, respectively. ACP-5862, the major human metabolite, is a relatively minor component in the systemic circulation and accountes for 6.1% and 8.1% of the AUC0-t total radioactivity in male and female dog plasma, respectively[1].
ACP-5862 (1 or 10 μM) has reversible protein binding of 98.6%, 99.8%, 94.3%, 98.6% in mouse, rat, dog, and human plasma[1].
| | IC 50 | CYP2C8; CYP3A4 |
| | Acalabrutinib Metabolite 27 Preparation Products And Raw materials |
|